Human Cell

pp 1–8 | Cite as

LncRNA SNHG8 promotes proliferation and invasion of gastric cancer cells by targeting the miR-491/PDGFRA axis

  • Peigen Zhang
  • Suting Li
  • Zhijun Chen
  • Yan Lu
  • Huanyao ZhangEmail author
Research Article


This study aimed to investigate the effects of long non-coding small nucleolar RNA host gene 8 (SNHG8) on the proliferation and invasion of gastric cancer (GC). The GC tissues and adjacent normal tissues from 30 patients were collected. Human GC cell lines, including AGS, SGC-7901, MKN-1, and BGC-803 and normal human gastric epithelial cell line GES-1 were purchased and cultured. The Cell Counting Kit-8 and Western blots were used to access cell proliferation, and platelet-derived growth factor receptor α (PDGFRA) expression, respectively. qRT-PCR was used to evaluate the expression of SNHG8 and miRNA-491. A transwell assay was applied to evaluate cell invasion. This study illustrated that SNHG8 expression was upregulated in GC tissues, as well as in cell lines. Moreover, knockdown of SNHG8 inhibited GC cell proliferation and invasion. Significantly, we determined that miRNA-491 was not only downregulated in stomach cancer but also inhibited GC cell progression induced by SNHG8. Further investigation demonstrated that SNHG8 promoted the proliferation and invasion of GC cells by targeting the miR-491/PDGFRA axis. LncRNA SNHG8 promoted the proliferation and invasion of GC cells by targeting the miR-491/PDGFRA axis, which might provide new insight for potential therapeutic strategies for GC in the future.


SNHG8 Gastric cancer miRNA-491 PDFRA 


Author contributions

PZ and SL performed the experiments. ZC and YL analyzed the data. HZ designed the study and drafted the manuscript.



Compliance with ethical standards

Conflict of interest

The authors have declared that no competing interests exist.


  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394–424.CrossRefGoogle Scholar
  2. 2.
    Kim SY, Yoon MJ, Park YI, Kim MJ, Nam B, Park SR. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment. Gastric Cancer. 2018;21:453–63.CrossRefGoogle Scholar
  3. 3.
    Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Ichiro T, Kato J, Takayama T. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 2017;20:517–26.CrossRefGoogle Scholar
  4. 4.
    Russo AE, Strong VE. Gastric cancer etiology and management in Asia and the West. Annu Rev Med. 2018;70:353–67.CrossRefGoogle Scholar
  5. 5.
    Reo M, Hiromu S. Long noncoding RNA involvement in cancer. BMB Rep. 2012;45:604–11.CrossRefGoogle Scholar
  6. 6.
    Wright C, Kirschner M, Cheng Y, O’Byrne K, Gray S, Schelch K, Mir A, Klebe S, McCaughan B, Zandwijk NV, Reid G. Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM). PLoS One. 2013;8:e70940.CrossRefGoogle Scholar
  7. 7.
    Lu PW, Li L, Wang F, Gu YT. Effects of long non-coding RNA HOST2 on cell migration and invasion by regulating MicroRNA let-7b in breast cancer. J Cell Biochem. 2018;119:4570–80.CrossRefGoogle Scholar
  8. 8.
    Chen Y, Yu X, Xu Y, Shen H. Identification of dysregulated lncRNAs profiling and metastasis-associated lncRNAs in colorectal cancer by genome-wide analysis. Cancer Med. 2017;6:2321–30.CrossRefGoogle Scholar
  9. 9.
    Shi X, Wang X, Hua Y. LncRNA GACAT1 promotes gastric cancer cell growth, invasion and migration by regulating MiR-149-mediated of ZBTB2 and SP1. J Cancer. 2018;9:3715–22.CrossRefGoogle Scholar
  10. 10.
    Li C, Chen J, Zhang K, Feng B, Wang R, Chen L. Progress and prospects of long noncoding RNAs (lncRNAs) in hepatocellular carcinoma. Cell Physiol Biochem. 2015;36:423–34.CrossRefGoogle Scholar
  11. 11.
    Wang Y, Gao S, Liu G, Jia R, Fan D, Feng X. Microarray expression profile analysis of long non-coding RNAs in human gastric cardiac adenocarcinoma. Cell Physiol Biochem. 2014;33:1225–38.CrossRefGoogle Scholar
  12. 12.
    Chen C, Zhang Z, Li J, Sun Y. SNHG8 is identified as a key regulator in non-small-cell lung cancer progression sponging to miR-542-3p by targeting CCND1/CDK6. Onco Targets Ther. 2018;11:6081–90.CrossRefGoogle Scholar
  13. 13.
    Dong J, Teng F, Guo W, Yang J, Ding G, Fu Z. lncRNA SNHG8 promotes the tumorigenesis and metastasis by sponging miR-149-5p and predicts tumor recurrence in hepatocellular carcinoma. Cell Physiol Biochem. 2018;51:2262–74.CrossRefGoogle Scholar
  14. 14.
    Song Y, Zou L, Li J, Shen ZP, Cai YL, Wu XD. LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 2018;22:8161–8.PubMedGoogle Scholar
  15. 15.
    Huang T, Ji Y, Hu D, Chen B, Zhang H, Li C, Chen G, Luo X, Zheng XW, Lin X. SNHG8 is identified as a key regulator of epstein-barr virus(EBV)-associated gastric cancer by an integrative analysis of lncRNA and mRNA expression. Oncotarget. 2016;7:80990–1002.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Xu Y, Hou R, Lu Q, Zhang Y, Chen L, Zheng Y, Hu B. MiR-491-5p negatively regulates cell proliferation and motility by targeting PDGFRA in prostate cancer. Am J Cancer Res. 2017;7:2545–53.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Iida M, Ikeda F, Hata J, Hirakawa Y, Ohara T, Mukai N, Yoshida D, Yonemoto K, Esaki M, Kitazono T, Kiyohara Y, Ninomiya T. Development and validation of a risk assessment tool for gastric cancer in a general Japanese population. Gastric Cancer. 2018;21:383–90.CrossRefGoogle Scholar
  18. 18.
    S. RL, M. KD and J. A, Cancer Statistics, 2017., CA Cancer J Clin (2017).Google Scholar
  19. 19.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. Cancer J Clin. 2016;66:115–32.CrossRefGoogle Scholar
  20. 20.
    Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, Meilleroux J, Baumann A, Vendrely V, Ducreux M, Michel P. Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Digest Liver Dis. 2018;50:768–79.CrossRefGoogle Scholar
  21. 21.
    Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;12–14:e535–47.CrossRefGoogle Scholar
  22. 22.
    Yu T, Wang L, Li W, Zuo Q, Li M, Zou Q, Xiao B. Downregulation of miR-491-5p promotes gastric cancer metastasis by regulating SNAIL and FGFR4. Cancer Sci. 2018;109:1393–403.CrossRefGoogle Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Peigen Zhang
    • 1
  • Suting Li
    • 2
  • Zhijun Chen
    • 3
  • Yan Lu
    • 4
  • Huanyao Zhang
    • 1
    Email author
  1. 1.Department of Emergency ServicesZengcheng District People’s Hospital of GuangzhouGuangzhouPeople’s Republic of China
  2. 2.Department of NursingZengcheng District People’s Hospital of GuangzhouGuangzhouChina
  3. 3.Department of Outpatient Internal MedicineZengcheng District People’s Hospital of GuangzhouGuangzhouChina
  4. 4.Department of SurgeryZengcheng District People’s Hospital of GuangzhouGuangzhouChina

Personalised recommendations